HBpF	O
-	O
proBDNF	B-GP
:	O
A	O
New	O
Tool	O
for	O
the	O
Analysis	O
of	O
Pro	O
-	O
Brain	B-GP
Derived	I-GP
Neurotrophic	I-GP
Factor	I-GP
Receptor	I-GP
Signaling	O
and	O
Cell	O
Biology	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
PG	O
PAB	O
.	O

Performed	O
the	O
experiments	O
:	O
PG	O
JG	O
GD	O
AD	O
.	O

Analyzed	O
the	O
data	O
:	O
PG	O
PS	O
PAB	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
VS	O
GD	O
PS	O
.	O

Wrote	O
the	O
paper	O
:	O
PG	O
PS	O
PAB	O
.	O

Neurotrophins	B-GP
activate	O
intracellular	O
signaling	O
pathways	O
necessary	O
for	O
neuronal	O
survival	O
,	O
growth	O
and	O
apoptosis	O
.	O

The	O
most	O
abundant	O
neurotrophin	B-GP
in	O
the	O
adult	O
brain	O
,	O
brain	B-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
BDNF	B-GP
),	O
is	O
first	O
synthesized	O
as	O
a	O
proBDNF	B-GP
precursor	O
and	O
recent	O
studies	O
have	O
demonstrated	O
that	O
proBDNF	B-GP
can	O
be	O
secreted	O
and	O
that	O
it	O
functions	O
as	O
a	O
ligand	O
for	O
a	O
receptor	O
complex	O
containing	O
p75NTR	B-GP
and	O
sortilin	B-GP
.	O

Activation	O
of	O
proBDNF	B-GP
receptors	I-GP
mediates	O
growth	O
cone	O
collapse	O
,	O
reduces	O
synaptic	O
activity	O
,	O
and	O
facilitates	O
developmental	O
apoptosis	O
of	O
motoneurons	O
but	O
the	O
precise	O
signaling	O
cascades	O
have	O
been	O
difficult	O
to	O
discern	O
.	O

To	O
address	O
this	O
,	O
we	O
have	O
engineered	O
,	O
expressed	O
and	O
purified	O
HBpF	O
-	O
proBDNF	B-GP
,	O
an	O
expression	O
construct	O
containing	O
a	O
6X	O
-	O
HIS	O
tag	O
,	O
a	O
biotin	O
acceptor	O
peptide	O
(	O
BAP	O
)	O
sequence	O
,	O
a	O
PreScission	O
™	O
Protease	B-GP
cleavage	O
site	O
and	O
a	O
FLAG	O
-	O
tag	O
attached	O
to	O
the	O
N	O
-	O
terminal	O
part	O
of	O
murine	O
proBDNF	B-GP
.	O

Intact	O
HBpF	O
-	O
proBDNF	B-GP
has	O
activities	O
indistinguishable	O
from	O
its	O
wild	O
-	O
type	O
counterpart	O
and	O
can	O
be	O
used	O
to	O
purify	O
proBDNF	B-GP
signaling	O
complexes	O
or	O
to	O
monitor	O
proBDNF	B-GP
endocytosis	O
and	O
retrograde	O
transport	O
.	O

HBpF	O
-	O
proBDNF	B-GP
will	O
be	O
useful	O
for	O
characterizing	O
proBDNF	B-GP
signaling	O
complexes	O
and	O
for	O
deciphering	O
the	O
role	O
of	O
proBDNF	B-GP
in	O
neuronal	O
development	O
,	O
synapse	O
function	O
and	O
neurodegenerative	B-DS
disease	I-DS
.	O

Introduction	O

The	O
four	O
mammalian	O
neurotrophins	B-GP
comprise	O
a	O
family	O
of	O
related	O
secreted	O
factors	O
required	O
for	O
differentiation	O
,	O
survival	O
,	O
development	O
and	O
death	O
of	O
specific	O
populations	O
of	O
neurons	O
and	O
non	O
-	O
neuronal	O
cells	O
.	O

The	O
effects	O
of	O
the	O
neurotrophins	B-GP
are	O
mediated	O
by	O
binding	O
to	O
TrkA	B-GP
,	O
TrkB	B-GP
and	O
TrkC	B-GP
receptor	I-GP
tyrosine	B-GP
kinases	I-GP
and	O
to	O
the	O
p75	B-GP
neurotrophin	I-GP
receptor	I-GP
(	O
p75NTR	B-GP
).	O

The	O
Trk	B-GP
receptors	I-GP
play	O
critical	O
roles	O
mediating	O
neuronal	O
survival	O
and	O
growth	O
and	O
are	O
important	O
modulators	O
of	O
synaptic	O
function	O
[	O
1	O
].	O

p75NTR	B-GP
is	O
a	O
component	O
of	O
distinct	O
cell	O
surface	O
signaling	O
platforms	O
that	O
function	O
to	O
induce	O
apoptosis	O
and	O
mediate	O
neuronal	O
growth	O
inhibition	O
.	O

However	O
,	O
p75NTR	B-GP
also	O
acts	O
as	O
a	O
Trk	B-GP
co	I-GP
-	I-GP
receptor	I-GP
that	O
increases	O
the	O
binding	O
specificity	O
and	O
affinity	O
of	O
Trk	B-GP
receptors	I-GP
for	O
neurotrophins	B-GP
[	O
2	O
,	O
3	O
].	O

Neurotrophins	B-GP
are	O
produced	O
as	O
proforms	O
of	O
approximately	O
240	O
amino	O
acids	O
that	O
are	O
cleaved	O
by	O
furins	B-GP
and	O
proconvertases	B-GP
to	O
yield	O
mature	O
neurotrophins	B-GP
of	O
about	O
120	O
amino	O
acids	O
[	O
3	O
].	O

The	O
main	O
functions	O
ascribed	O
to	O
the	O
neurotrophin	B-GP
prodomain	O
include	O
facilitating	O
neurotrophin	B-GP
folding	O
and	O
directing	O
neurotrophins	B-GP
to	O
the	O
regulated	O
secretory	O
pathway	O
[	O
4	O
–	O
6	O
].	O

Several	O
recent	O
studies	O
have	O
indicated	O
that	O
nerve	B-GP
growth	I-GP
factor	I-GP
(	O
NGF	B-GP
)	O
and	O
brain	B-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
BDNF	B-GP
)	O
are	O
secreted	O
from	O
cells	O
as	O
prodomain	O
-	O
containing	O
forms	O
(	O
proNGF	B-GP
and	O
proBDNF	B-GP
,	O
respectively	O
)	O
[	O
7	O
–	O
9	O
].	O

In	O
some	O
types	O
of	O
primary	O
neurons	O
and	O
in	O
endothelial	O
cells	O
,	O
proneurotrophin	B-GP
binding	O
to	O
the	O
p75NTR	B-GP
-	O
sortilin	B-GP
receptor	O
complex	O
is	O
a	O
potent	O
apoptotic	O
stimulus	O
[	O
7	O
,	O
9	O
,	O
10	O
]	O
and	O
several	O
studies	O
have	O
demonstrated	O
the	O
importance	O
of	O
proNGF	B-GP
and	O
proBDNF	B-GP
for	O
inducing	O
apoptosis	O
in	O
vivo	O
[	O
7	O
,	O
10	O
–	O
15	O
].	O

Further	O
,	O
several	O
groups	O
have	O
reported	O
that	O
proBDNF	B-GP
functions	O
as	O
an	O
important	O
modulator	O
of	O
synaptic	O
structure	O
and	O
function	O
[	O
16	O
,	O
17	O
].	O

Although	O
it	O
seems	O
certain	O
that	O
the	O
pro	O
-	O
neurotrophins	B-GP
play	O
physiological	O
roles	O
,	O
the	O
precise	O
signaling	O
pathways	O
that	O
are	O
regulated	O
by	O
these	O
ligands	O
remain	O
uncertain	O
.	O

Recent	O
data	O
have	O
shown	O
that	O
another	O
VPS10	B-GP
family	O
member	O
,	O
SORCS2	B-GP
,	O
functions	O
as	O
a	O
p75NTR	B-GP
binding	O
partner	O
that	O
acts	O
in	O
a	O
pro	O
-	O
neurotrophin	B-GP
binding	O
complex	O
[	O
18	O
]	O
but	O
the	O
precise	O
signaling	O
cascades	O
and	O
cell	O
biological	O
responses	O
evoked	O
downstream	O
of	O
the	O
p75NTR	B-GP
-	O
sortilin	B-GP
or	O
the	O
p75NTR	B-GP
-	O
SorCS2	B-GP
complexes	O
remain	O
largely	O
uncharacterized	O
.	O

Details	O
of	O
proBDNF	B-GP
signaling	O
and	O
cell	O
biology	O
have	O
been	O
slow	O
to	O
emerge	O
,	O
in	O
part	O
due	O
to	O
a	O
lack	O
of	O
robust	O
tools	O
.	O

p75NTR	B-GP
is	O
a	O
member	O
of	O
the	O
TNF	B-GP
receptor	I-GP
superfamily	O
and	O
several	O
major	O
findings	O
on	O
receptors	O
of	O
this	O
class	O
have	O
relied	O
on	O
the	O
development	O
of	O
tagged	O
ligands	O
that	O
can	O
be	O
used	O
to	O
identify	O
and	O
track	O
receptor	O
complexes	O
in	O
cell	O
biological	O
assays	O
[	O
19	O
].	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
tagged	O
proBDNF	B-GP
isoform	O
that	O
can	O
be	O
easily	O
purified	O
and	O
readily	O
used	O
for	O
tandem	O
affinity	O
purification	O
or	O
for	O
ligand	O
-	O
labeling	O
approaches	O
.	O

This	O
reagent	O
exhibits	O
normal	O
biological	O
activity	O
and	O
can	O
be	O
used	O
to	O
isolate	O
proBDNF	B-GP
receptor	I-GP
complexes	O
.	O

We	O
believe	O
it	O
will	O
prove	O
helpful	O
in	O
the	O
characterization	O
of	O
proBDNF	B-GP
signaling	O
mechanisms	O
.	O

Material	O
and	O
Methods	O

Animals	B-OG

All	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
McGill	O
University	O
Animal	O
Care	O
Committee	O
and	O
were	O
in	O
compliance	O
with	O
the	O
guidelines	O
of	O
the	O
Canadian	O
Council	O
on	O
Animal	O
Care	O
.	O

Male	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
(	O
6	O
–	O
8	O
weeks	O
old	O
)	O
and	O
rat	B-OG
Sprague	I-OG
-	I-OG
Dawley	I-OG
(	O
7	O
–	O
8	O
days	O
old	O
)	O
were	O
obtained	O
from	O
Charles	O
River	O
Canada	O
.	O

Animals	B-OG
were	O
housed	O
under	O
standard	O
conditions	O
with	O
a	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
and	O
had	O
free	O
access	O
to	O
water	O
and	O
food	O
.	O

Cell	O
culture	O

HEK293T	O
cells	O
were	O
maintained	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
(	O
DME	O
)	O
medium	O
containing	O
10	O
%	O
bovine	O
calf	O
serum	O
,	O
2	O
mM	O
L	O
-	O
Glutamine	O
and	O
100	O
μg	O
/	O
ml	O
penicillin	O
and	O
100	O
μg	O
/	O
ml	O
streptomycin	O
in	O
a	O
humidified	O
37	O
°	O
C	O
incubator	O
with	O
5	O
%	O
CO2	O
.	O

PC12	O
cells	O
were	O
maintained	O
in	O
DME	O
containing	O
6	O
%	O
bovine	O
calf	O
serum	O
and	O
6	O
%	O
deactivated	O
horse	B-OG
serum	O
,	O
2mM	O
L	O
-	O
glutamine	O
and	O
100μg	O
/	O
ml	O
penicillin	O
and	O
100μg	O
/	O
ml	O
streptomycin	O
in	O
a	O
humidified	O
37	O
°	O
C	O
incubator	O
with	O
10	O
%	O
CO2	O
.	O

Dissociated	O
hippocampal	O
neurons	O
were	O
prepared	O
from	O
embryonic	O
day	O
15	O
CD1	B-OG
mouse	I-OG
embryos	O
(	O
Charles	O
River	O
).	O

Briefly	O
,	O
the	O
hippocampus	O
was	O
dissected	O
out	O
in	O
Hank	O
’	O
s	O
balanced	O
salt	O
solution	O
buffered	O
with	O
Hepes	O
and	O
dissociated	O
via	O
trypsin	B-GP
/	O
EDTA	O
treatment	O
.	O

Cells	O
were	O
seeded	O
on	O
poly	O
-	O
D	O
-	O
lysin	O
coated	O
coverslips	O
and	O
fed	O
Neurobasal	O
media	O
supplemented	O
with	O
2	O
%	O
B27	O
(	O
Invitrogen	O
),	O
1	O
%	O
L	O
-	O
glutamine	O
(	O
Wisent	O
)	O
and	O
1	O
%	O
penicillin	O
/	O
streptomicyin	O
(	O
Wisent	O
)]	O
and	O
astrocyte	O
conditioned	O
media	O
for	O
10	O
days	O
in	O
vitro	O
,	O
prior	O
to	O
treatment	O
with	O
BDNF	B-GP
,	O
proBDNF	B-GP
or	O
HBpFproBDNF	O
.	O

All	O
cell	O
culture	O
reagents	O
were	O
obtained	O
from	O
Hyclone	O
(	O
Logan	O
,	O
UT	O
).	O

Treatments	O
and	O
reagents	O

For	O
phospho	O
-	O
Trk	B-GP
and	O
phospho	O
-	O
Erk	B-GP
activation	O
,	O
CGN	O
and	O
PC12	O
cells	O
were	O
incubated	O
in	O
serum	O
-	O
free	O
DME	O
supplemented	O
with	O
0	O
.	O
1	O
%	O
bovine	O
serum	O
albumin	B-GP
(	O
BSA	B-GP
)	O
and	O
2mM	O
L	O
-	O
glutamine	O
and	O
100μg	O
/	O
ml	O
penicillin	O
and	O
100μg	O
/	O
ml	O
streptomycin	O
(	O
DMEB	O
)	O
for	O
1h	O
prior	O
to	O
treatment	O
with	O
BDNF	B-GP
,	O
proBDNF	B-GP
and	O
HBpF	O
-	O
proBDNF	B-GP
.	O

The	O
anti	O
-	O
biotin	O
antibody	B-GP
was	O
from	O
Jackson	O
Immunoresearch	O
,	O
anti	O
-	O
Flag	O
and	O
anti	O
-	O
beta	B-GP
III	I-GP
-	I-GP
tubulin	I-GP
were	O
from	O
Sigma	O
,	O
anti	O
-	O
BDNF	B-GP
(	O
N	O
-	O
20	O
)	O
was	O
from	O
Santa	O
-	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
and	O
anti	O
phospho	O
-	O
TrkA	B-GP
(	O
Tyr490	O
)	O
was	O
from	O
Cell	O
Signaling	O
Technology	O
.	O

Antibodies	B-GP
against	O
p75NTR	B-GP
,	O
total	O
TrkA	B-GP
and	O
total	O
TrkB	B-GP
have	O
been	O
previously	O
described	O
[	O
20	O
–	O
23	O
].	O

Anti	O
-	O
Sortilin	B-GP
and	O
anti	O
-	O
SorCS2	B-GP
were	O
gifts	O
from	O
Dr	O
.	O
Barbara	O
Hempstead	O
,	O
Rhodamine	O
-	O
tagged	O
phalloidin	O
was	O
from	O
Life	O
technologies	O
and	O
Hoechst	O
33342	O
was	O
obtained	O
from	O
Molecular	O
Probes	O
.	O

Horseradish	B-OG
-	O
peroxidase	B-GP
-	O
conjugated	O
and	O
fluorescent	O
dye	O
-	O
conjugated	O
secondary	O
antibodies	B-GP
were	O
purchased	O
from	O
Jackson	O
ImmunoResearch	O
(	O
West	O
Grove	O
,	O
PA	O
).	O

BDNF	B-GP
(	O
B250	O
)	O
and	O
proBDNF	B-GP
(	O
B240	O
)	O
was	O
purchased	O
from	O
Alomone	O
labs	O
(	O
Jerusalem	O
,	O
Israel	O
).	O

Cy3	O
-	O
Streptavidin	B-GP
was	O
purchased	O
from	O
Invitrogen	O
and	O
GM6001	O
was	O
purchased	O
from	O
Calbiochem	O
.	O

Generation	O
of	O
recombinant	O
HBpF	O
-	O
proBDNF	B-GP

Tags	O
were	O
introduced	O
into	O
mouse	B-OG
proBDNF	B-GP
using	O
PCR	O
overlap	O
and	O
the	O
QuikChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Agilent	O
).	O

Inserted	O
sequences	O
encoded	O
the	O
following	O
amino	O
acid	O
sequence	O
:	O
6xHis	O
-	O
tag	O
was	O
HHHHHH	O
;	O
Biotin	O
Acceptor	O
Peptide	O
(	O
BAP	O
)	O
was	O
GLNDIFEAQKIEWH	O
;	O
linker	O
sequence	O
was	O
SGGGGS	O
,	O
PreScission	O
™	O
Protease	B-GP
sequence	O
was	O
LEVLFQG	O
and	O
FLAG	O
was	O
DYKDDDDK	O
.	O

The	O
QuikChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
was	O
used	O
to	O
mutate	O
the	O
furin	B-GP
-	O
cleavage	O
site	O
of	O
proBDNF	B-GP
from	O
KR	O
to	O
AA	O
(	O
nt	O
.	O

409	O
to	O
414	O
).	O

Fidelity	O
of	O
the	O
complete	O
HBpF	O
-	O
proBDNF	B-GP
construct	O
was	O
confirmed	O
by	O
sequencing	O
and	O
the	O
construct	O
was	O
subcloned	O
into	O
pDest12	O
.	O
2	O
for	O
mammalian	O
expression	O
.	O

HBpF	O
-	O
proBDNF	B-GP
production	O
and	O
purification	O

HEK293T	O
cells	O
were	O
transfected	O
with	O
plasmids	O
encoding	O
HBpF	O
-	O
proBDNF	B-GP
and	O
BirA	B-GP
using	O
calcium	O
phosphate	O
transfection	O
.	O

Media	O
was	O
changed	O
16	O
hours	O
later	O
and	O
supplemented	O
with	O
100μM	O
D	O
-	O
Biotin	O
.	O

48h	O
later	O
,	O
media	O
was	O
collected	O
and	O
cells	O
were	O
lysed	O
in	O
20mM	O
Tris	O
(	O
pH	O
7	O
.	O
5	O
),	O
300mM	O
NaCl	O
,	O
10mM	O
imidazole	O
and	O
a	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
Roche	O
).	O

After	O
sonication	O
and	O
centrifugation	O
to	O
remove	O
insoluble	O
components	O
,	O
the	O
supernatant	O
was	O
rotated	O
with	O
Ni	O
-	O
NTA	O
beads	O
(	O
Qiagen	O
)	O
for	O
1h	O
at	O
4	O
°	O
C	O
.	O

Beads	O
were	O
washed	O
twice	O
in	O
wash	O
buffer	O
(	O
20mM	O
TRIS	O
pH	O
7	O
.	O
5	O
,	O
300mM	O
NaCl	O
,	O
20mM	O
Imidazole	O
)	O
and	O
then	O
incubated	O
30	O
minutes	O
in	O
elution	O
buffer	O
(	O
20mM	O
TRIS	O
pH	O
7	O
.	O
5	O
,	O
300mM	O
NaCl	O
,	O
500mM	O
Imidazole	O
).	O

The	O
eluate	O
was	O
dialysed	O
against	O
20mM	O
Tris	O
(	O
pH	O
7	O
.	O
5	O
)	O
+	O
300mM	O
NaCl	O
and	O
then	O
concentrated	O
in	O
centrifugal	O
filters	O
(	O
Amicon	O
Ultra	O
,	O
Millipore	O
).	O

Protein	O
Stabilizing	O
Cocktail	O
(	O
4x	O
)	O
and	O
Halt	O
Protease	B-GP
Inhibitor	O
Cocktail	O
(	O
100x	O
)	O
(	O
both	O
from	O
ThermoScientific	O
)	O
were	O
added	O
to	O
the	O
concentrated	O
sample	O
and	O
the	O
protein	O
was	O
stored	O
at	O
-	O
80	O
°	O
C	O
.	O

HBpF	O
-	O
proBDNF	B-GP
samples	O
concentration	O
was	O
determined	O
on	O
dot	O
-	O
blots	O
,	O
with	O
commercial	O
BDNF	B-GP
serving	O
as	O
a	O
reference	O
.	O

To	O
produce	O
negative	O
controls	O
,	O
the	O
identical	O
procedure	O
was	O
performed	O
on	O
extracts	O
of	O
HEK293	O
cells	O
transfected	O
with	O
BirA	B-GP
plasmid	O
alone	O
and	O
final	O
concentrated	O
eluates	O
were	O
used	O
in	O
functional	O
assays	O
.	O

To	O
fluorescently	O
label	O
HBpF	O
-	O
proBDNF	B-GP
,	O
HBpF	O
-	O
proBDNF	B-GP
bound	O
to	O
Ni	O
-	O
NTA	O
beads	O
was	O
incubated	O
with	O
Cy3	O
-	O
Streptavidin	B-GP
(	O
30μg	O
/	O
ml	O
)	O
for	O
1h	O
at	O
4	O
°	O
C	O
.	O

After	O
extensive	O
washes	O
,	O
the	O
Cy3	O
-	O
streptavidin	B-GP
:	O
HBpF	O
-	O
proBDNF	B-GP
complex	O
was	O
eluted	O
and	O
concentrated	O
as	O
described	O
above	O
.	O

Modified	O
tandem	O
affinity	O
enrichment	O

PC12	O
cells	O
were	O
exposed	O
to	O
HBpF	O
-	O
proBDNF	B-GP
,	O
washed	O
,	O
lysed	O
in	O
lysis	O
buffer	O
(	O
20mM	O
Tris	O
(	O
pH7	O
.	O
5	O
),	O
50mM	O
NaCl	O
,	O
1mM	O
CaCl2	O
,	O
0	O
.	O
1	O
%	O
Triton	O
-	O
X100	O
and	O
protease	B-GP
inhibitor	O
cocktail	O
,	O
EDTA	O
-	O
free	O
(	O
Roche	O
))	O
then	O
rotated	O
with	O
streptavidin	B-GP
beads	O
for	O
1h	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
twice	O
with	O
lysis	O
buffer	O
,	O
beads	O
were	O
incubated	O
for	O
16h	O
at	O
4	O
°	O
C	O
with	O
PreScission	O
™	O
Protease	B-GP
(	O
20mM	O
Tris	O
(	O
pH7	O
.	O
5	O
),	O
150mM	O
NaCl	O
,	O
1mM	O
DTT	O
and	O
0	O
.	O
5mM	O
EDTA	O
),	O
using	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
PreScission	O
™	O
Protease	B-GP
,	O
GE	O
).	O

The	O
eluate	O
was	O
then	O
collected	O
,	O
diluted	O
in	O
4X	O
Laemmli	O
sample	O
buffer	O
,	O
and	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
.	O

Immunolabeling	O

For	O
immunoblotting	O
,	O
samples	O
were	O
boiled	O
5	O
minutes	O
,	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
on	O
nitrocellulose	O
membranes	O
.	O

Membranes	O
were	O
blocked	O
in	O
TBST	O
(	O
10mM	O
TRIS	O
pH8	O
.	O
0	O
,	O
150mM	O
NaCl	O
,	O
2	O
%	O
Tween	O
20	O
)	O
supplemented	O
with	O
5	O
%	O
dried	O
skim	O
milk	O
powder	O
(	O
or	O
with	O
2	O
%	O
BSA	B-GP
for	O
immunoblotting	O
phospho	O
-	O
antibodies	B-GP
).	O

Incubation	O
with	O
primary	O
and	O
secondary	O
antibodies	B-GP
was	O
performed	O
in	O
blocking	O
solution	O
.	O

Membranes	O
were	O
washed	O
extensively	O
in	O
TBST	O
after	O
each	O
incubation	O
and	O
immunoreactive	O
bands	O
were	O
detected	O
using	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
,	O
Pierce	O
).	O

For	O
immunocytochemistry	O
,	O
cells	O
were	O
grown	O
on	O
coverslips	O
coated	O
with	O
poly	O
-	O
L	O
-	O
lysine	O
.	O

After	O
treatment	O
,	O
cells	O
were	O
fixed	O
for	O
30	O
minutes	O
at	O
room	O
temperature	O
in	O
4	O
%	O
formaldehyde	O
,	O
permeabilized	O
for	O
5	O
minutes	O
with	O
0	O
.	O
2	O
%	O
Triton	O
X	O
-	O
100	O
in	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
),	O
washed	O
once	O
with	O
PBS	O
,	O
blocked	O
for	O
1h	O
in	O
0	O
.	O
02	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
%	O
BSA	B-GP
in	O
PBS	O
and	O
then	O
incubated	O
overnight	O
with	O
the	O
primary	O
antibody	B-GP
diluted	O
in	O
0	O
.	O
02	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
%	O
BSA	B-GP
in	O
PBS	O
.	O

The	O
coverslips	O
are	O
washed	O
three	O
times	O
with	O
PBS	O
,	O
then	O
incubated	O
with	O
the	O
secondary	O
antibody	B-GP
in	O
0	O
.	O
02	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
%	O
BSA	B-GP
in	O
PBS	O
.	O

Finally	O
coverslip	O
were	O
mounted	O
in	O
an	O
anti	O
-	O
fading	O
mounting	O
media	O
(	O
Dako	O
)	O
and	O
kept	O
at	O
4	O
°	O
C	O
until	O
imaging	O
.	O

Growth	O
cone	O
collapse	O
assay	O

CGNs	O
were	O
exposed	O
to	O
HBpF	O
-	O
proBDNF	B-GP
for	O
1	O
hour	O
then	O
fixed	O
and	O
stained	O
with	O
antibodies	B-GP
directed	O
against	O
beta	B-GP
-	I-GP
III	I-GP
tubulin	I-GP
and	O
phalloidin	O
.	O

Images	O
were	O
collected	O
on	O
a	O
Zeiss	O
AxioCam	O
microscope	O
.	O

Collapsed	O
growth	O
cones	O
are	O
defined	O
as	O
those	O
with	O
no	O
lamellipodia	O
and	O
not	O
more	O
than	O
two	O
filopodia	O
.	O

At	O
least	O
50	O
growth	O
cones	O
were	O
analyzed	O
for	O
each	O
data	O
point	O
and	O
statistical	O
significance	O
was	O
established	O
using	O
two	O
-	O
tailed	O
unpaired	O
t	O
-	O
tests	O
.	O

Brain	O
slice	O
preparation	O
and	O
electrophysiological	O
recordings	O

Briefly	O
,	O
6	O
to	O
8	O
week	O
-	O
old	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
anaesthetized	O
with	O
ketamine	O
:	O
xylamine	O
cocktail	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
perfused	O
with	O
ice	O
-	O
cold	O
choline	O
chloride	O
-	O
based	O
artificial	O
cerebrospinal	O
fluid	O
(	O
ACSF	O
)	O
containing	O
(	O
in	O
mM	O
):	O
110	O
choline	O
-	O
Cl	O
,	O
1	O
.	O
25	O
NaH2PO4	O
,	O
25	O
NaHCO3	O
,	O
7	O
MgCl2	O
,	O
0	O
.	O
5	O
CaCl2	O
,	O
2	O
.	O
5	O
KCl	O
,	O
7	O
glucose	O
,	O
3	O
pyruvic	O
acid	O
and	O
1	O
.	O
3	O
ascorbic	O
acid	O
,	O
pH	O
7	O
.	O
4	O
bubbled	O
with	O
carbogen	O
(	O
O2	O
95	O
%,	O
CO2	O
5	O
%).	O

Semicoronal	O
horizontal	O
slices	O
(	O
300	O
μm	O
)	O
containing	O
the	O
entorhinal	O
cortex	O
(	O
EC	O
)	O
from	O
the	O
retrohippocampal	O
region	O
were	O
produced	O
using	O
a	O
VT1000	O
vibratome	O
(	O
Leica	O
,	O
Ontario	O
,	O
Canada	O
)	O
in	O
the	O
same	O
choline	O
chloride	O
-	O
based	O
solution	O
.	O

Slices	O
were	O
maintained	O
in	O
ACSF	O
containing	O
(	O
in	O
mM	O
):	O
124	O
NaCl	O
,	O
3	O
KCl	O
,	O
26	O
NaHCO3	O
,	O
1	O
.	O
8	O
MgSO4	O
,	O
1	O
.	O
25	O
NaH2PO4	O
,	O
10	O
glucose	O
,	O
1	O
.	O
6	O
CaCl2	O
for	O
1h	O
before	O
recording	O
at	O
room	O
temperature	O
(	O
22	O
–	O
24	O
°	O
C	O
)	O
for	O
1	O
hour	O
prior	O
to	O
recordings	O
.	O

For	O
electrophysiology	O
,	O
slices	O
were	O
placed	O
in	O
a	O
recording	O
chamber	O
perfused	O
by	O
gravity	O
at	O
a	O
speed	O
of	O
1	O
–	O
2	O
ml	O
/	O
min	O
with	O
ACSF	O
containing	O
kynurenic	O
acid	O
(	O
2	O
mM	O
)	O
and	O
picrotoxin	O
(	O
100	O
μM	O
).	O

A	O
near	O
-	O
infrared	O
charged	O
-	O
coupled	O
device	O
camera	O
was	O
used	O
to	O
visualize	O
layer	O
V	O
entorhinal	O
neurons	O
.	O

The	O
temperature	O
of	O
perfusion	O
solution	O
was	O
maintained	O
at	O
32	O
–	O
34	O
°	O
C	O
.	O

Patch	O
pipettes	O
(	O
5	O
–	O
9	O
MΩ	O
)	O
were	O
pulled	O
on	O
a	O
Brown	O
Flaming	O
puller	O
(	O
P	O
-	O
97	O
,	O
Sutter	O
Instruments	O
,	O
Novato	O
,	O
CA	O
)	O
using	O
borosilicate	O
glass	O
electrode	O
(	O
Sutter	O
Instruments	O
)	O
and	O
filled	O
with	O
an	O
intracellular	O
solution	O
composed	O
of	O
(	O
in	O
mM	O
):	O
120	O
K	O
-	O
gluconate	O
,	O
10	O
HEPES	O
,	O
0	O
.	O
2	O
EGTA	O
,	O
20	O
KCl	O
,	O
2	O
MgCl2	O
,	O
7	O
diTrisP	O
-	O
Creatine	O
,	O
4	O
Na2ATP	O
and	O
0	O
.	O
3	O
NaGTP	O
(	O
pH	O
adjusted	O
to	O
7	O
.	O
3	O
with	O
KOH	O
).	O

Tight	O
seals	O
(>	O
5	O
GΩ	O
)	O
were	O
obtained	O
by	O
applying	O
constant	O
negative	O
pressure	O
.	O

Electrical	O
signals	O
were	O
amplified	O
using	O
an	O
Axopatch	O
200B	O
amplifier	O
(	O
Molecular	O
Devices	O
,	O
Sunnyvale	O
,	O
CA	O
),	O
low	O
-	O
pass	O
-	O
filtered	O
at	O
10	O
kHz	O
,	O
digitized	O
at	O
50	O
kHz	O
via	O
a	O
Digitadata	O
1322A	O
interface	O
(	O
Molecular	O
Devices	O
),	O
and	O
stored	O
on	O
a	O
computer	O
using	O
pClamp9	O
.	O
2	O
software	O
(	O
Molecular	O
Devices	O
)	O
for	O
off	O
-	O
line	O
analysis	O
.	O

In	O
this	O
study	O
,	O
all	O
neurons	O
displayed	O
a	O
resting	O
membrane	O
potential	O
ranging	O
from	O
−	O
55	O
to	O
−	O
75	O
mV	O
.	O

The	O
holding	O
current	O
was	O
around	O
0	O
pA	O
and	O
slightly	O
adjusted	O
to	O
obtain	O
a	O
membrane	O
potential	O
of	O
–	O
60	O
mV	O
.	O

Electrophysiological	O
data	O
were	O
analyzed	O
using	O
Clampfit	O
9	O
.	O
2	O
.	O
1	O
.	O
8	O
(	O
Axon	O
instruments	O
).	O

Values	O
are	O
expressed	O
as	O
mean	O
+/-	O
S	O
.	O
E	O
.	O
M	O
.	O

Firing	O
frequency	O
was	O
defined	O
as	O
the	O
average	O
spiking	O
frequency	O
within	O
20	O
s	O
after	O
the	O
depolarizing	O
current	O
pulse	O
(	O
1	O
s	O
duration	O
,	O
100	O
pA	O
).	O

Plateau	O
amplitude	O
was	O
defined	O
as	O
the	O
difference	O
between	O
the	O
mean	O
membrane	O
potential	O
(	O
mV	O
)	O
measured	O
at	O
baseline	O
before	O
the	O
pulse	O
and	O
the	O
mean	O
membrane	O
potential	O
measured	O
during	O
the	O
steady	O
-	O
state	O
phase	O
of	O
persistent	O
firing	O
.	O

Results	O

Construction	O
,	O
production	O
,	O
and	O
purification	O
of	O
HBpF	O
-	O
proBDNF	B-GP

Tandem	O
affinity	O
purification	O
(	O
TAP	O
)	O
has	O
emerged	O
as	O
a	O
powerful	O
technique	O
for	O
identifying	O
protein	O
-	O
protein	O
interactions	O
and	O
has	O
been	O
widely	O
used	O
as	O
method	O
for	O
identifying	O
protein	O
complexes	O
.	O

The	O
basic	O
method	O
involves	O
placing	O
two	O
tags	O
on	O
a	O
protein	O
,	O
typically	O
separated	O
by	O
a	O
proteolytic	O
site	O
;	O
affinity	O
purification	O
is	O
performed	O
via	O
the	O
distal	O
tag	O
,	O
the	O
bound	O
protein	O
is	O
then	O
released	O
from	O
its	O
support	O
using	O
a	O
protease	B-GP
that	O
targets	O
the	O
cleavage	O
site	O
between	O
the	O
tags	O
,	O
and	O
the	O
complex	O
is	O
further	O
enriched	O
by	O
affinity	O
purification	O
against	O
the	O
remaining	O
tag	O
[	O
24	O
,	O
25	O
].	O

Here	O
,	O
we	O
developed	O
a	O
TAP	O
-	O
compatible	O
form	O
of	O
proBDNF	B-GP
that	O
has	O
several	O
unique	O
features	O
(	O
Fig	O
1A	O
).	O

From	O
the	O
N	O
-	O
terminal	O
end	O
,	O
HBpF	O
-	O
proBDNF	B-GP
consists	O
of	O
the	O
endogenous	O
gene	O
’	O
s	O
signal	O
peptide	O
,	O
a	O
6xHis	O
-	O
tag	O
(	O
H	O
),	O
a	O
biotin	O
acceptor	O
peptide	O
(	O
B	O
),	O
a	O
linker	O
,	O
a	O
PreScission	O
™	O
Protease	B-GP
cleavage	O
site	O
(	O
p	O
)	O
and	O
a	O
Flag	O
-	O
tag	O
(	O
F	O
);	O
this	O
extension	O
is	O
followed	O
by	O
murine	O
proBDNF	B-GP
containing	O
two	O
site	O
directed	O
mutations	O
,	O
R129A	O
and	O
R130A	O
.	O

The	O
6xHis	O
-	O
tag	O
is	O
used	O
to	O
purify	O
HBpF	O
-	O
proBDNF	B-GP
from	O
conditioned	O
media	O
or	O
from	O
mammalian	O
cell	O
lysates	O
with	O
Ni	O
-	O
NTA	O
beads	O
(	O
Fig	O
1A	O
).	O

The	O
biotin	O
acceptor	O
peptide	O
allows	O
HBpF	O
-	O
proBDNF	B-GP
to	O
be	O
metabolically	O
biotinylated	O
in	O
cells	O
expressing	O
a	O
BirA	B-GP
biotin	B-GP
ligase	I-GP
and	O
enables	O
high	O
-	O
stringency	O
affinity	O
purification	O
on	O
streptavidin	B-GP
or	O
can	O
be	O
used	O
to	O
label	O
ligand	O
with	O
avidin	B-GP
-	O
tagged	O
fluorophores	O
.	O

Bound	O
HBpF	O
-	O
proBDNF	B-GP
and	O
associated	O
proteins	O
are	O
released	O
from	O
streptavidin	B-GP
beads	O
by	O
cleavage	O
by	O
PreScission	O
™	O
Protease	B-GP
at	O
4	O
°	O
C	O
.	O

This	O
cleavage	O
allows	O
Flag	O
-	O
tagged	O
proBDNF	B-GP
(	O
F	O
-	O
proBDNF	B-GP
)	O
to	O
be	O
generated	O
and	O
allows	O
it	O
and	O
associated	O
binding	O
partners	O
to	O
be	O
recovered	O
as	O
an	O
eluted	O
product	O
with	O
a	O
high	O
degree	O
of	O
purification	O
.	O

The	O
R129A	O
/	O
R130A	O
mutations	O
remove	O
the	O
native	O
dibasic	O
site	O
that	O
is	O
cleaved	O
to	O
produce	O
BDNF	B-GP
from	O
proBDNF	B-GP
.	O

HBpF	O
-	O
proBDNF	B-GP
design	O
and	O
production	O
.	O

A	O
.	O

Schematic	O
representation	O
of	O
recombinant	O
HBpF	O
-	O
proBDNF	B-GP
protein	O
.	O

HBpF	O
-	O
proBDNF	B-GP
contains	O
a	O
signal	O
peptide	O
,	O
an	O
amino	O
-	O
terminal	O
6xHis	O
-	O
tag	O
,	O
followed	O
by	O
a	O
Biotin	O
-	O
Acceptor	O
-	O
Peptide	O
(	O
BAP	O
)	O
sequence	O
,	O
a	O
linker	O
(	O
L	O
),	O
a	O
PreScission	O
™	O
Protease	B-GP
(	O
PP	O
)	O
cleavage	O
site	O
and	O
a	O
Flag	O
-	O
tag	O
(	O
Flag	O
).	O

The	O
ProBDNF	B-GP
sequence	O
has	O
been	O
mutated	O
with	O
a	O
KR	O
to	O
AA	O
mutation	O
at	O
the	O
furin	B-GP
dibasic	O
cleavage	O
site	O
between	O
the	O
pro	O
-	O
domain	O
and	O
the	O
mature	O
part	O
of	O
BDNF	B-GP
.	O

B	O
.	O

HEK293T	O
cells	O
were	O
transfected	O
with	O
HBpF	O
-	O
proBDNF	B-GP
and	O
BirA	B-GP
plasmids	O
.	O

After	O
Ni	O
-	O
NTA	O
pulldown	O
and	O
cleavage	O
with	O
the	O
PreScission	O
™	O
Protease	B-GP
,	O
the	O
eluates	O
were	O
analyzed	O
by	O
Western	O
blot	O
and	O
blotted	O
with	O
anti	O
-	O
biotin	O
,	O
anti	O
-	O
Flag	O
and	O
anti	O
-	O
BDNF	B-GP
.	O

C	O
.	O

Purified	O
HBpF	O
-	O
proBDNF	B-GP
was	O
incubated	O
with	O
PC12	O
cells	O
lysates	O
,	O
without	O
a	O
protease	B-GP
inhibitors	O
,	O
for	O
1h	O
at	O
room	O
temperature	O
.	O

Incubation	O
of	O
HBpF	O
-	O
proBDNF	B-GP
with	O
lysis	O
buffer	O
for	O
1h	O
at	O
room	O
temperature	O
was	O
used	O
as	O
a	O
control	O
.	O

Immunoblots	O
against	O
BDNF	B-GP
were	O
performed	O
to	O
visualize	O
the	O
degradation	O
of	O
HBpF	O
-	O
proBDNF	B-GP
.	O

HBpF	O
-	O
proBDNF	B-GP
was	O
overexpressed	O
in	O
HEK293T	O
cells	O
together	O
with	O
BirA	B-GP
biotin	B-GP
ligase	I-GP
in	O
media	O
supplemented	O
with	O
100μM	O
biotin	O
.	O

After	O
48	O
hours	O
,	O
cells	O
were	O
lysed	O
and	O
incubated	O
with	O
Ni	O
-	O
NTA	O
beads	O
for	O
2	O
hours	O
and	O
washed	O
extensively	O
.	O

Bound	O
HBpF	O
-	O
proBDNF	B-GP
was	O
then	O
eluted	O
with	O
500mM	O
imidazole	O
or	O
exposed	O
to	O
PreScission	O
™	O
Protease	B-GP
(	O
1	O
unit	O
/	O
100μg	O
of	O
protein	O
)	O
for	O
12	O
hours	O
at	O
4	O
°	O
C	O
.	O

The	O
primary	O
HBpF	O
-	O
proBDNF	B-GP
product	O
is	O
mainly	O
a	O
35kDa	O
protein	O
,	O
with	O
a	O
less	O
abundant	O
subsidiary	O
product	O
of	O
33	O
kDa	O
.	O

We	O
have	O
not	O
directly	O
assessed	O
HBpF	O
-	O
proBDNF	B-GP
glycosylation	O
but	O
based	O
on	O
a	O
previous	O
analysis	O
,	O
it	O
is	O
likely	O
that	O
two	O
isoforms	O
reflect	O
distinct	O
proBDNF	B-GP
glycosylation	O
states	O
[	O
26	O
].	O

Both	O
isoforms	O
are	O
readily	O
detected	O
by	O
anti	O
-	O
biotin	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
BDNF	B-GP
antibodies	B-GP
(	O
Fig	O
1B	O
,	O
lane	O
1	O
).	O

After	O
exposure	O
to	O
precision	O
protease	B-GP
,	O
the	O
predominant	O
and	O
subsidiary	O
product	O
shift	O
to	O
molecular	O
weights	O
of	O
32	O
kDa	O
and	O
30	O
kDa	O
,	O
respectively	O
.	O

As	O
expected	O
,	O
these	O
products	O
are	O
detected	O
by	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
BDNF	B-GP
but	O
not	O
by	O
anti	O
-	O
biotin	O
and	O
correspond	O
to	O
liberated	O
Flag	O
-	O
proBDNF	B-GP
isoforms	O
(	O
F	O
-	O
proBDNF	B-GP
).	O

To	O
test	O
if	O
proBDNF	B-GP
can	O
become	O
cleaved	O
during	O
the	O
process	O
of	O
cell	O
lysis	O
,	O
HBpF	O
-	O
proBDNF	B-GP
bound	O
to	O
Ni	O
-	O
NTA	O
beads	O
was	O
exposed	O
to	O
cell	O
lysates	O
,	O
without	O
protease	B-GP
inhibitor	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O
Fig	O
1C	O
shows	O
that	O
HBpF	O
-	O
proBDNF	B-GP
remained	O
intact	O
under	O
these	O
conditions	O
.	O

Biological	O
properties	O
of	O
HBpF	O
-	O
proBDNF	B-GP

Recent	O
studies	O
have	O
indicated	O
that	O
proBDNF	B-GP
induces	O
growth	O
cone	O
collapse	O
in	O
murine	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
neurons	O
and	O
in	O
cortical	O
neurons	O
[	O
15	O
].	O

To	O
determine	O
if	O
purified	O
recombinant	O
HBpF	O
-	O
proBDNF	B-GP
can	O
elicit	O
this	O
effect	O
in	O
central	O
neurons	O
,	O
we	O
evaluated	O
growth	O
cone	O
collapse	O
in	O
hippocampal	O
neurons	O
.	O

Hippocampal	O
neurons	O
were	O
left	O
untreated	O
or	O
were	O
exposed	O
to	O
purified	O
HBpF	O
-	O
proBDNF	B-GP
(	O
25ng	O
/	O
ml	O
and	O
100ng	O
/	O
ml	O
)	O
for	O
one	O
hour	O
.	O

As	O
a	O
positive	O
control	O
,	O
we	O
tested	O
identical	O
concentrations	O
of	O
commercial	O
proBDNF	B-GP
(	O
Alomone	O
Labs	O
)	O
and	O
as	O
a	O
negative	O
control	O
,	O
we	O
exposed	O
cells	O
to	O
eluates	O
derived	O
from	O
cells	O
expressing	O
only	O
BirA	B-GP
(	O
see	O
Methods	O
).	O

Quantification	O
of	O
growth	O
cone	O
collapse	O
showed	O
that	O
the	O
BirA	B-GP
eluate	O
had	O
no	O
effect	O
on	O
growth	O
cone	O
morphology	O
whereas	O
both	O
HBpF	O
-	O
proBDNF	B-GP
and	O
commercial	O
proBDNF	B-GP
increased	O
hippocampal	O
growth	O
cone	O
collapse	O
(	O
Fig	O
2A	O
and	O
2B	O
).	O

The	O
dose	O
required	O
to	O
elicit	O
the	O
effect	O
was	O
similar	O
with	O
the	O
two	O
preparations	O
,	O
with	O
25	O
ng	O
/	O
ml	O
increasing	O
growth	O
cone	O
collapse	O
by	O
~	O
40	O
%.	O

HBpF	O
-	O
proBDNF	B-GP
induces	O
growth	O
cone	O
collapse	O
.	O

Following	O
2	O
days	O
in	O
culture	O
,	O
hippocampal	O
neuronal	O
culture	O
were	O
stimulated	O
with	O
different	O
concentrations	O
of	O
HBpF	O
-	O
proBDNF	B-GP
or	O
proBDNF	B-GP
(	O
25ng	O
/	O
ml	O
and	O
100ng	O
/	O
ml	O
)	O
for	O
1h	O
.	O

Ni	O
-	O
NTA	O
eluate	O
from	O
cells	O
expressing	O
only	O
BirA	B-GP
was	O
used	O
as	O
a	O
negative	O
control	O
.	O

Cells	O
were	O
then	O
fixed	O
and	O
immunostained	O
against	O
beta	B-GP
-	I-GP
III	I-GP
-	I-GP
tubulin	I-GP
(	O
Tuj	O
-	O
1	O
)	O
and	O
phalloidin	O
(	O
scale	O
bar	O
=	O
10μm	O
).	O

Quantification	O
of	O
growth	O
cone	O
-	O
collapse	O
was	O
done	O
on	O
three	O
independent	O
experiments	O
and	O
50	O
growth	O
-	O
cones	O
were	O
counted	O
for	O
each	O
experiment	O
(	O
unpaired	O
two	O
-	O
tailed	O
t	O
-	O
test	O
,	O
*	O
indicates	O
a	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
;	O
bars	O
indicate	O
standard	O
error	O
).	O

We	O
have	O
recently	O
shown	O
that	O
proBDNF	B-GP
,	O
working	O
through	O
p75NTR	B-GP
,	O
has	O
a	O
profound	O
effect	O
on	O
the	O
excitability	O
of	O
layer	O
V	O
pyramidal	O
neurons	O
in	O
the	O
entorhinal	O
cortex	O
[	O
27	O
].	O

These	O
neurons	O
normally	O
exhibit	O
persistent	O
firing	O
when	O
exposed	O
to	O
the	O
muscarinic	O
agonist	O
carbachol	O
but	O
this	O
effect	O
is	O
strongly	O
suppressed	O
in	O
the	O
presence	O
of	O
commercial	O
proBDNF	B-GP
(	O
Fig	O
3A	O
).	O

To	O
test	O
if	O
HBpF	O
-	O
proBDNF	B-GP
is	O
also	O
capable	O
of	O
suppressing	O
persistent	O
activity	O
,	O
murine	O
entorhinal	O
cortical	O
slices	O
were	O
perfused	O
with	O
10μM	O
carbachol	O
(	O
CCh	O
)	O
for	O
10	O
minutes	O
,	O
stimulated	O
with	O
100pA	O
of	O
depolarizing	O
current	O
for	O
1s	O
and	O
recordings	O
were	O
performed	O
in	O
whole	O
cell	O
patch	O
clamp	O
.	O

The	O
same	O
slices	O
were	O
then	O
exposed	O
to	O
HBpF	O
-	O
proBDNF	B-GP
(	O
2ng	O
/	O
ml	O
).	O
Fig	O
3A	O
shows	O
that	O
the	O
persistent	O
activity	O
induced	O
in	O
slices	O
incubated	O
in	O
10μM	O
carbachol	O
is	O
strongly	O
suppressed	O
by	O
HBpF	O
-	O
proBDNF	B-GP
,	O
with	O
both	O
plateau	O
amplitude	O
and	O
firing	O
frequency	O
significantly	O
decreased	O
upon	O
HBpF	O
-	O
proBDNF	B-GP
exposure	O
(	O
Fig	O
3B	O
).	O

Importantly	O
,	O
this	O
effect	O
is	O
reversible	O
as	O
subsequent	O
washout	O
of	O
HBpF	O
-	O
proBDNF	B-GP
restores	O
persistent	O
activity	O
.	O

Thus	O
,	O
HBpF	O
-	O
proBDNF	B-GP
is	O
functionally	O
indistinguishable	O
from	O
wild	O
-	O
type	O
proBDNF	B-GP
in	O
this	O
setting	O
.	O

HBpF	O
-	O
proBDNF	B-GP
inhibits	O
carbachol	O
(	O
CCh	O
)-	O
induced	O
persistent	O
firing	O
in	O
cortical	O
pyramidal	O
neurons	O
.	O

A	O
.	O

Representative	O
trace	O
of	O
current	O
-	O
clamp	O
recording	O
from	O
pyramidal	O
neuron	O
in	O
layer	O
V	O
of	O
the	O
entorhinal	O
cortex	O
.	O

Slices	O
were	O
perfused	O
with	O
10μM	O
CCh	O
and	O
the	O
persistent	O
activity	O
was	O
produced	O
by	O
a	O
short	O
depolarization	O
(	O
1s	O
,	O
100pA	O
).	O

HBpF	O
-	O
proBDNF	B-GP
at	O
2ng	O
/	O
ml	O
was	O
next	O
added	O
in	O
presence	O
of	O
10μM	O
CCh	O
during	O
10	O
minutes	O
(	O
first	O
cut	O
in	O
the	O
trace	O
)	O
and	O
cells	O
were	O
stimulated	O
.	O

HBpF	O
-	O
proBDNF	B-GP
was	O
removed	O
by	O
perfusing	O
a	O
solution	O
containing	O
only	O
10μM	O
CCh	O
for	O
10	O
minutes	O
(	O
second	O
cut	O
in	O
the	O
trace	O
)	O
and	O
before	O
the	O
stimulation	O
of	O
the	O
cells	O
.	O

B	O
.	O

Quantification	O
of	O
the	O
plateau	O
amplitude	O
and	O
frequency	O
of	O
the	O
persistent	O
activity	O
(	O
unpaired	O
two	O
-	O
tailed	O
t	O
-	O
test	O
,	O
*	O
indicates	O
a	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
;	O
bars	O
indicate	O
standard	O
error	O
).	O

Previous	O
studies	O
have	O
established	O
that	O
proBDNF	B-GP
bound	O
to	O
fluorescently	O
labeled	O
antibodies	B-GP
is	O
endocytosed	O
through	O
a	O
p75NTR	B-GP
-	O
dependent	O
pathway	O
[	O
9	O
].	O

To	O
determine	O
if	O
HBpF	O
-	O
proBDNF	B-GP
could	O
also	O
be	O
endocytosed	O
,	O
we	O
first	O
labelled	O
HBAP	O
-	O
proBDNF	B-GP
with	O
the	O
fluorophore	O
Cy3	O
-	O
Streptavidin	B-GP
.	O

For	O
this	O
,	O
biotinylated	O
HBpF	O
-	O
proBDNF	B-GP
was	O
bound	O
to	O
a	O
Ni	O
-	O
NTA	O
resin	O
and	O
then	O
incubated	O
with	O
a	O
Cy3	O
-	O
Streptavidin	B-GP
conjugate	O
for	O
1	O
hour	O
,	O
washed	O
extensively	O
,	O
and	O
then	O
eluted	O
with	O
imidazole	O
.	O

After	O
dialysis	O
and	O
quantification	O
,	O
Cy3	O
-	O
labelled	O
HBpF	O
-	O
proBDNF	B-GP
was	O
added	O
to	O
primary	O
cultures	O
of	O
hippocampal	O
neurons	O
for	O
periods	O
ranging	O
from	O
1	O
–	O
6	O
hours	O
.	O

At	O
the	O
end	O
of	O
the	O
incubation	O
period	O
,	O
cells	O
were	O
washed	O
in	O
low	O
pH	O
buffer	O
to	O
remove	O
surface	O
ligand	O
and	O
then	O
quantified	O
by	O
fluorescence	O
microscopy	O
.	O

Cy3	O
-	O
labelled	O
HBpF	O
-	O
proBDNF	B-GP
is	O
clearly	O
internalized	O
after	O
1	O
hour	O
of	O
incubation	O
and	O
levels	O
remain	O
stably	O
elevated	O
at	O
later	O
incubation	O
times	O
;	O
unconjugated	O
Cy3	O
-	O
streptavidin	B-GP
,	O
the	O
negative	O
control	O
for	O
these	O
experiments	O
,	O
did	O
not	O
accumulate	O
in	O
hippocampal	O
neuronal	O
cells	O
at	O
any	O
timepoint	O
examined	O
(	O
Fig	O
4	O
and	O
data	O
not	O
shown	O
).	O

Endocytosis	O
of	O
HBpF	O
-	O
proBDNF	B-GP
in	O
Hippocampal	O
neurons	O
.	O

Primary	O
hippocampal	O
neurons	O
cells	O
were	O
exposed	O
to	O
HBpF	O
-	O
proBDNF	B-GP
(	O
250	O
ng	O
/	O
ml	O
)	O
conjugated	O
to	O
Streptavidin	B-GP
-	O
Cy3	O
for	O
1h	O
to	O
6h	O
.	O

After	O
fixation	O
and	O
mounting	O
,	O
cells	O
were	O
analyzed	O
by	O
fluorescent	O
microscopy	O
.	O

Hoechst	O
staining	O
was	O
used	O
as	O
a	O
nuclear	O
marker	O
.	O

Quantification	O
of	O
fluorescence	O
intensity	O
was	O
performed	O
using	O
ImageJ	O
software	O
on	O
three	O
independent	O
experiments	O
.	O

100	O
cells	O
were	O
measured	O
for	O
each	O
experiment	O
.	O

(	O
unpaired	O
two	O
-	O
tailed	O
t	O
-	O
test	O
,	O
*	O
indicates	O
a	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
;	O
bars	O
indicate	O
standard	O
error	O
).	O

Mature	O
-	O
BDNF	B-GP
(	O
mBDNF	O
)	O
binds	O
TrkB	B-GP
and	O
p75NTR	B-GP
whereas	O
proBDNF	B-GP
selectively	O
binds	O
a	O
complex	O
containing	O
p75NTR	B-GP
and	O
sortilin	B-GP
or	O
p75NTR	B-GP
and	O
SorCS2	B-GP
[	O
2	O
,	O
3	O
,	O
28	O
,	O
29	O
].	O

To	O
confirm	O
that	O
HBpF	O
-	O
proBDNF	B-GP
does	O
not	O
activate	O
TrkB	B-GP
,	O
we	O
exposed	O
CGNs	O
to	O
mBDNF	O
(	O
25ng	O
/	O
ml	O
),	O
to	O
commercial	O
proBDNF	B-GP
(	O
2	O
and	O
25ng	O
/	O
ml	O
),	O
and	O
to	O
HBpF	O
-	O
proBDNF	B-GP
(	O
2	O
and	O
25ng	O
/	O
ml	O
)	O
for	O
30	O
min	O
and	O
then	O
performed	O
immunoblots	O
for	O
phospho	O
-	O
TrkB	B-GP
and	O
total	O
TrkB	B-GP
.	O
Fig	O
5A	O
shows	O
that	O
mBDNF	O
induces	O
robust	O
TrkB	B-GP
phosphorylation	O
whereas	O
commercial	O
proBDNF	B-GP
and	O
HBpF	O
-	O
proBDNF	B-GP
had	O
no	O
effect	O
on	O
TrkB	B-GP
phosphorylation	O
.	O

HBpF	O
-	O
proBDNF	B-GP
does	O
not	O
activate	O
TrkB	B-GP
receptors	I-GP
.	O

A	O
.	O

Following	O
2	O
days	O
in	O
culture	O
,	O
cerebellar	O
granule	O
neurons	O
were	O
stimulated	O
with	O
different	O
concentrations	O
of	O
HBpF	O
-	O
proBDNF	B-GP
(	O
2ng	O
/	O
ml	O
;	O
25ng	O
/	O
ml	O
and	O
100ng	O
/	O
ml	O
)	O
or	O
proBDNF	B-GP
(	O
2ng	O
/	O
ml	O
and	O
25ng	O
/	O
ml	O
)	O
for	O
30min	O
.	O

After	O
the	O
incubation	O
time	O
,	O
cells	O
were	O
lysed	O
immediately	O
in	O
sample	O
buffer	O
and	O
analyzed	O
by	O
Western	O
blot	O
against	O
phospho	O
-	O
Trk	B-GP
and	O
TrkB	B-GP
.	O

For	O
positive	O
and	O
negative	O
controls	O
,	O
CGN	O
were	O
treated	O
with	O
BDNF	B-GP
(	O
25ng	O
/	O
ml	O
)	O
or	O
with	O
BirA	B-GP
Ni	O
-	O
NTA	O
eluate	O
(	O
BirA	B-GP
),	O
as	O
indicated	O
.	O

HBpF	O
-	O
proBDNF	B-GP
can	O
be	O
used	O
to	O
isolate	O
p75NTR	B-GP
complexes	O

HBpF	O
-	O
proBDNF	B-GP
was	O
designed	O
to	O
identify	O
signaling	O
complexes	O
that	O
are	O
formed	O
by	O
proBDNF	B-GP
binding	O
to	O
p75NTR	B-GP
.	O

To	O
confirm	O
that	O
HBpF	O
-	O
proBDNF	B-GP
binds	O
to	O
p75NTR	B-GP
,	O
we	O
overexpressed	O
p75NTR	B-GP
and	O
sortilin	B-GP
either	O
alone	O
or	O
together	O
in	O
HEK293	O
cells	O
,	O
with	O
and	O
without	O
HBpF	O
-	O
proBDNF	B-GP
.	O

Cells	O
were	O
lysed	O
48h	O
after	O
transfection	O
,	O
HBpF	O
-	O
proBDNF	B-GP
was	O
purified	O
on	O
Ni	O
-	O
NTA	O
beads	O
,	O
eluted	O
using	O
imidazole	O
,	O
bound	O
to	O
streptavidin	B-GP
beads	O
,	O
then	O
incubated	O
with	O
PreScission	O
™	O
Protease	B-GP
.	O

Proteins	O
released	O
from	O
the	O
beads	O
by	O
PreScission	O
™	O
Protease	B-GP
cleavage	O
(	O
PP	O
eluate	O
)	O
were	O
then	O
collected	O
and	O
analyzed	O
by	O
immunoblot	O
.	O
Fig	O
6A	O
shows	O
that	O
HBpF	O
-	O
proBDNF	B-GP
was	O
detected	O
by	O
biotin	O
and	O
Flag	O
antibodies	B-GP
whereas	O
HBpF	O
-	O
proBDNF	B-GP
present	O
in	O
the	O
precision	O
protease	B-GP
eluate	O
was	O
detected	O
by	O
anti	O
-	O
Flag	O
but	O
not	O
by	O
anti	O
-	O
biotin	O
antibodies	B-GP
(	O
Fig	O
6B	O
).	O

This	O
demonstrates	O
that	O
the	O
protease	B-GP
treatment	O
effectively	O
cleaved	O
the	O
biotinylated	O
moiety	O
from	O
HBpF	O
-	O
proBDNF	B-GP
to	O
release	O
F	O
-	O
proBDNF	B-GP
from	O
the	O
beads	O
.	O

Interestingly	O
,	O
p75NTR	B-GP
is	O
co	O
-	O
purified	O
with	O
F	O
-	O
proBDNF	B-GP
in	O
cells	O
lacking	O
or	O
expressing	O
sortilin	B-GP
whereas	O
sortilin	B-GP
levels	O
present	O
within	O
the	O
F	O
-	O
proBDNF	B-GP
eluate	O
were	O
considerably	O
higher	O
in	O
the	O
presence	O
of	O
p75NTR	B-GP
.	O

Thus	O
,	O
the	O
sortilin	B-GP
-	O
proBDNF	B-GP
complex	O
appears	O
to	O
be	O
stabilized	O
in	O
the	O
presence	O
of	O
p75NTR	B-GP
.	O

HBpF	O
-	O
proBDNF	B-GP
can	O
be	O
isolated	O
by	O
a	O
modified	O
tandem	O
affinity	O
purification	O
protocol	O
.	O

A	O
.	O

HEK293T	O
cells	O
were	O
transfected	O
with	O
p75NTR	B-GP
,	O
Sortilin	B-GP
,	O
HBpF	O
-	O
proBDNF	B-GP
,	O
and	O
BirA	B-GP
expression	O
plasmid	O
as	O
indicated	O
.	O

48h	O
after	O
transfection	O
,	O
HEK293T	O
cells	O
were	O
lysed	O
(	O
input	O
)	O
and	O
pulled	O
-	O
down	O
on	O
Ni	O
-	O
NTA	O
beads	O
.	O

The	O
Ni	O
-	O
NTA	O
eluate	O
was	O
then	O
pulled	O
-	O
down	O
on	O
SA	O
beads	O
and	O
then	O
cleaved	O
by	O
PP	O
overnight	O
(	O
PP	O
eluate	O
).	O

Samples	O
were	O
analyzed	O
by	O
immunoblotting	O
for	O
p75NTR	B-GP
,	O
sortilin	B-GP
,	O
biotin	O
and	O
the	O
Flag	O
tag	O
.	O

To	O
determine	O
if	O
HBpF	O
-	O
proBDNF	B-GP
could	O
be	O
used	O
to	O
isolate	O
endogenous	O
receptor	O
complexes	O
in	O
untransfected	O
cells	O
,	O
PC12	O
cells	O
were	O
exposed	O
to	O
HBpF	O
-	O
proBDNF	B-GP
for	O
3	O
hours	O
,	O
then	O
lysed	O
and	O
subjected	O
to	O
streptavidin	B-GP
pulldown	O
followed	O
by	O
cleavage	O
with	O
PreScission	O
™	O
Protease	B-GP
.	O

Since	O
metalloproteases	B-GP
can	O
cleave	O
proBDNF	B-GP
or	O
p75NTR	B-GP
,	O
in	O
parallel	O
we	O
tested	O
whether	O
adding	O
GM6001	O
,	O
an	O
inhibitor	O
of	O
metalloproteases	B-GP
increased	O
the	O
yield	O
of	O
endogenous	O
p75NTR	B-GP
or	O
SorCS2	B-GP
pulled	O
out	O
using	O
this	O
procedure	O
.	O
Fig	O
7	O
shows	O
that	O
p75NTR	B-GP
and	O
SorCS2	B-GP
were	O
readily	O
co	O
-	O
purified	O
in	O
a	O
complex	O
with	O
HBpF	O
-	O
proBDNF	B-GP
but	O
only	O
in	O
cells	O
incubated	O
with	O
GM6001	O
(	O
9μM	O
).	O

Interestingly	O
,	O
HBpF	O
-	O
proBDNF	B-GP
was	O
not	O
detected	O
in	O
pullouts	O
from	O
cells	O
lacking	O
GM6001	O
,	O
indicating	O
that	O
endogenous	O
metalloproteases	B-GP
may	O
target	O
bound	O
HBpF	O
-	O
proBDNF	B-GP
for	O
destruction	O
(	O
Fig	O
7	O
).	O

HBpF	O
-	O
proBDNF	B-GP
interacts	O
with	O
endogenous	O
p75NTR	B-GP
and	O
SorCS2	B-GP
in	O
PC12	O
cells	O
.	O

PC12	O
cells	O
were	O
stimulated	O
with	O
HBpF	O
-	O
proBDNF	B-GP
(	O
100μg	O
/	O
ml	O
)	O
with	O
or	O
without	O
9μM	O
GM6001	O
for	O
3h	O
.	O

BirA	B-GP
Ni	O
-	O
NTA	O
eluate	O
was	O
used	O
as	O
control	O
treatment	O
.	O

After	O
stimulation	O
,	O
cells	O
were	O
lysed	O
and	O
HBpF	O
-	O
proBDNF	B-GP
and	O
associated	O
protein	O
were	O
recovered	O
on	O
SA	O
beads	O
.	O

Cleavage	O
with	O
PP	O
was	O
performed	O
for	O
16	O
hours	O
and	O
the	O
resulting	O
PP	O
eluate	O
was	O
collected	O
.	O

Cell	O
lysates	O
(	O
Input	O
)	O
and	O
PP	O
eluate	O
samples	O
were	O
then	O
analyzed	O
by	O
immunoblotting	O
for	O
p75NTR	B-GP
,	O
SorCS2	B-GP
and	O
FLAG	O
.	O

Discussion	O

ProBDNF	B-GP
has	O
emerged	O
as	O
regulator	O
of	O
cell	O
morphology	O
,	O
neuronal	O
excitability	O
and	O
cell	O
death	O
[	O
2	O
,	O
30	O
]	O
However	O
,	O
knowledge	O
of	O
the	O
signaling	O
mechanisms	O
activated	O
by	O
this	O
peptide	O
remains	O
rudimentary	O
.	O

Here	O
,	O
we	O
describe	O
the	O
development	O
and	O
characterization	O
of	O
a	O
multi	O
-	O
tagged	O
form	O
of	O
proBDNF	B-GP
that	O
can	O
be	O
used	O
in	O
cell	O
biological	O
assays	O
and	O
in	O
for	O
biochemical	O
experiments	O
that	O
are	O
designed	O
to	O
identify	O
and	O
characterize	O
receptor	O
complexes	O
.	O

We	O
show	O
that	O
HBpF	O
-	O
proBDNF	B-GP
can	O
be	O
readily	O
over	O
-	O
expressed	O
in	O
HEK293	O
cells	O
and	O
easily	O
affinity	O
purified	O
by	O
a	O
Ni	O
-	O
NTA	O
procedure	O
.	O

Furthermore	O
,	O
the	O
intact	O
tagged	O
HBpF	O
-	O
proBDNF	B-GP
construct	O
functions	O
identically	O
to	O
its	O
untagged	O
counterpart	O
within	O
in	O
vitro	O
settings	O
.	O

Pro	O
-	O
BDNF	B-GP
has	O
been	O
shown	O
to	O
induce	O
growth	O
-	O
cone	O
collapse	O
[	O
5	O
,	O
13	O
,	O
31	O
,	O
32	O
]	O
and	O
we	O
found	O
that	O
HBpF	O
-	O
proBDNF	B-GP
elicits	O
the	O
same	O
response	O
.	O

We	O
have	O
recently	O
shown	O
that	O
activation	O
of	O
the	O
proBDNF	B-GP
-	O
p75NTR	B-GP
transduction	O
cascade	O
inhibits	O
persistent	O
firing	O
in	O
the	O
entorhinal	O
cortex	O
[	O
27	O
]	O
and	O
here	O
,	O
we	O
demonstrated	O
that	O
HBpF	O
-	O
proBDNF	B-GP
reproduces	O
the	O
electrophysiological	O
effect	O
of	O
proBDNF	B-GP
in	O
this	O
setting	O
.	O

Moreover	O
HBpF	O
-	O
proBDNF	B-GP
bound	O
to	O
Cy3	O
-	O
streptavidin	B-GP
was	O
readily	O
endocytosed	O
by	O
hippocampal	O
neuronal	O
cells	O
and	O
did	O
not	O
induce	O
TrkB	B-GP
activation	O
in	O
CGNs	O
.	O

Thus	O
,	O
HBpF	O
-	O
proBDNF	B-GP
exhibits	O
the	O
receptor	O
activation	O
profile	O
previously	O
established	O
for	O
proBDNF	B-GP
.	O

The	O
effects	O
of	O
proBDNF	B-GP
reported	O
here	O
occur	O
over	O
a	O
large	O
concentration	O
range	O
,	O
consistent	O
with	O
previous	O
studies	O
.	O

In	O
the	O
growth	O
cone	O
collapse	O
assays	O
performed	O
by	O
Sun	O
et	O
al	O
(	O
2012	O
),	O
proBDNF	B-GP
elicited	O
maximal	O
effects	O
at	O
30	O
and	O
100	O
ng	O
/	O
ml	O
[	O
15	O
]	O
similar	O
to	O
the	O
25	O
and	O
100	O
ng	O
/	O
ml	O
concentrations	O
used	O
here	O
.	O

We	O
recently	O
examined	O
the	O
effect	O
of	O
proBDNF	B-GP
on	O
persistent	O
activity	O
in	O
entorhinal	O
cortical	O
neurons	O
and	O
in	O
this	O
cell	O
type	O
,	O
maximal	O
effects	O
were	O
elicited	O
at	O
considerably	O
lower	O
proBDNF	B-GP
concentrations	O
(	O
2	O
ng	O
/	O
ml	O
)	O
[	O
27	O
].	O

We	O
speculate	O
tat	O
cell	O
-	O
specific	O
differences	O
in	O
proBDNF	B-GP
dose	O
-	O
dependency	O
may	O
reflect	O
the	O
existence	O
of	O
unique	O
p75NTR	B-GP
-	O
containing	O
proBDNF	B-GP
receptor	I-GP
complexes	O
in	O
various	O
cell	O
types	O
.	O

We	O
also	O
show	O
that	O
HBpF	O
-	O
proBDNF	B-GP
can	O
be	O
used	O
to	O
identify	O
receptor	O
complexes	O
.	O

Using	O
a	O
two	O
-	O
step	O
purification	O
procedure	O
(	O
streptavidin	B-GP
pulldown	O
of	O
the	O
biotinylated	O
HBpF	O
-	O
proBDNF	B-GP
then	O
cleavage	O
of	O
the	O
construct	O
by	O
the	O
PreScission	O
™	O
Protease	B-GP
),	O
we	O
established	O
that	O
HBpF	O
-	O
proBDNF	B-GP
can	O
bind	O
to	O
a	O
complex	O
of	O
p75NTR	B-GP
and	O
sortilin	B-GP
when	O
they	O
are	O
overexpressed	O
in	O
HEK293	O
cells	O
and	O
it	O
interacts	O
with	O
endogenous	O
p75NTR	B-GP
and	O
SorCS2	B-GP
in	O
PC12	O
cells	O
.	O

Epitope	O
tagged	O
ligands	O
have	O
proven	O
to	O
be	O
valuable	O
tools	O
for	O
analyzing	O
receptor	O
complexes	O
,	O
especially	O
in	O
the	O
TNF	B-GP
receptor	I-GP
superfamily	O
field	O
.	O

For	O
example	O
,	O
early	O
studies	O
employed	O
ligands	O
tagged	O
with	O
a	O
single	O
FLAG	O
or	O
Fc	O
tag	O
[	O
24	O
,	O
25	O
]	O
showed	O
that	O
TNF	B-GP
receptor	I-GP
I	I-GP
-	O
mediated	O
apoptosis	O
occurs	O
through	O
activation	O
of	O
two	O
sequential	O
signaling	O
complexes	O
.	O

More	O
recent	O
studies	O
,	O
using	O
tagging	O
procedures	O
similar	O
to	O
that	O
described	O
here	O
,	O
resulted	O
in	O
the	O
identification	O
of	O
LUBAC	B-GP
,	O
a	O
receptor	O
-	O
associated	O
linear	B-GP
ubiquitin	I-GP
chain	I-GP
assembly	I-GP
complex	I-GP
[	O
19	O
,	O
33	O
].	O

Hence	O
HBpF	O
-	O
proBDNF	B-GP
will	O
be	O
a	O
useful	O
reagent	O
for	O
identifying	O
proBDNF	B-GP
receptor	I-GP
complexes	O
and	O
for	O
unraveling	O
specific	O
signaling	O
mechanisms	O
that	O
mediate	O
the	O
various	O
physiological	O
functions	O
of	O
proBDNF	B-GP
.	O

